Literature DB >> 2205284

Kallikreins and kinins: mediators in inflammatory joint disease?

K Worthy1, C D Figueroa, P A Dieppe, K D Bhoola.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2205284      PMCID： PMC2002290     

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN： 0959-9673            Impact factor:   1.925


× No keyword cloud information.
  54 in total

1.  The relationship of structure and function in human Hageman factor. The association of enzymatic and binding activities with separate regions of the molecule.

Authors:  S D Revak; C G Cochrane
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

2.  Intracellular enzymes and kinin enzymes in synovial fluid in joint diseases. Origin and relation to disease category.

Authors:  M K Jasani; M Katori; G P Lewis
Journal:  Ann Rheum Dis       Date:  1969-09       Impact factor: 19.103

3.  Plasma kinins in synovial exudates.

Authors:  V Eisen
Journal:  Br J Exp Pathol       Date:  1970-06

4.  Urates and kinin formation in synovial fluid.

Authors:  V Eisen
Journal:  Proc R Soc Med       Date:  1966-04

5.  Observations on sheep with polyarthritis produced by an agent of the psittacosis-lymphogranuloma venereum-trachoma group.

Authors:  W L Norton; J Storz
Journal:  Arthritis Rheum       Date:  1967-02

6.  Prostaglandins, kinin and inflammation in the rat.

Authors:  G Thomas; G B West
Journal:  Br J Pharmacol       Date:  1974-02       Impact factor: 8.739

7.  Synovial protease/inhibitor ratios in erosive and nonerosive arthropathies.

Authors:  M H Pritchard
Journal:  Ann Rheum Dis       Date:  1984-02       Impact factor: 19.103

8.  Thymus-derived lymphocytes and their interactions with macrophages are required for the production of osteoclast-activating factor in the mouse.

Authors:  M Horowitz; A Vignery; R K Gershon; R Baron
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

9.  Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor.

Authors:  J H Griffin; C G Cochrane
Journal:  Proc Natl Acad Sci U S A       Date:  1976-08       Impact factor: 11.205

10.  Absence of binding of pancreatic and urinary kallikreins to alpha 2-macroglobulin.

Authors:  E Vahtera; U Hamberg
Journal:  Biochem J       Date:  1976-08-01       Impact factor: 3.857
View more
  7 in total

1.  Immunolocalization of renal kallikrein-like substance in rat urinary bladder.

Authors:  C Orfila; G Bompart; J C Lepert; J M Suc; J P Girolami
Journal:  Histochem J       Date:  1993-09

2.  Augmented plasma and tissue kallikrein like activity in synovial fluid of patients with inflammatory articular diseases.

Authors:  N Volpe-Júnior; E A Donadi; I F Carvalho; M L Reis
Journal:  Inflamm Res       Date:  1996-04       Impact factor: 4.575

3.  Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution.

Authors:  B A Katz; B Liu; M Barnes; E B Springman
Journal:  Protein Sci       Date:  1998-04       Impact factor: 6.725

4.  Specificity of human tissue kallikrein towards substrates containing Phe-Phe pair of amino acids.

Authors:  D C Pimenta; J Chao; L Chao; M A Juliano; L Juliano
Journal:  Biochem J       Date:  1999-04-15       Impact factor: 3.857

5.  IL-4 and IL-13 inhibit IL-1β and TNF-α induced kinin B1 and B2 receptors through a STAT6-dependent mechanism.

Authors:  P P C Souza; A B Brechter; R I Reis; C A S Costa; P Lundberg; U H Lerner
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

6.  High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis.

Authors:  Reuben Gobezie; Alvin Kho; Bryan Krastins; David A Sarracino; Thomas S Thornhill; Michael Chase; Peter J Millett; David M Lee
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

7.  An Extensive Study of the Functional Polymorphisms of Kinin-Kallikrein System in Rheumatoid Arthritis Susceptibility.

Authors:  Anthoula Chatzikyriakidou; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Arch Rheumatol       Date:  2017-09-13       Impact factor: 1.472
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.